Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group

Journal of Clinical Oncology

Volumn 19, Issue 10, 2001, Pages 2596-2606

  Mouridsen, Henning ^b   Gershanovich, Mikhail ^b   Sun, Yan ^b   Pérez Carrión, Ramón ^b   Boni, Corrado ^b   Monnier, Alain ^b   Apffelstaedt, Justus ^b   Smith, Robert ^b   Sleeboom, Harm P ^b   Jänicke, Fritz ^b   Pluzanska, Anna ^b   Dank, Magdolna ^b   Becquart, Dominique ^b   Bapsy, Poonamalle P ^b   Salminen, Eeva ^b   Snyder, Ray ^b   Lassus, Mercedes ^b   Verbeek, J Arnold ^b   Staffler, Beatrix ^b   Chaudri Ross, Hilary A ^a   Dugan, Margaret ^b   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 0343584508     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.10.2596     Document Type: Article

References (30)

1. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 109:219-228, 1988
2. Santen RJ, Manni A, Harvey H, et al: Endocrine treatment of breast cancer in women. Endocr Rev 11:1-45, 1990 (suppl 2)
3. Rose C, Mouridsen HT: Endocrine therapy of advanced breast cancer. Acta Oncol 27:721-728, 1988
4. Muss HB, Wells HB, Paschold EH, et al: Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association. J Clin Oncol 6:1098-1106, 1988
5. Gill PG, Gebski V, Snyder R, et al: Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 4:741-744, 1993
6. Castiglione-Gertsch M, Pampallona S, Varini M, et al: Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 4:735-740, 1993
7. Gale KE, Anderson JW, Tormey DC, et al: Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73:354-361, 1994
8. Muss HB, Case DL, Atkins JN, et al: Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study. J Clin Oncol 12:1630-1638, 1994
9. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14:2000-2011, 1996
10. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
11. Gershanovich M, Chaudri HA, Campos D, et al: Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9:639-645, 1998
12. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18:1399-1411, 2000
13. Hamilton A. Piccart M: The third-generation non-steroidal aromatase inhibitors. A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10:377-384, 1999
14. Nabholtz A, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000
15. Bonneterre J, Thürlimann B, Robertson JFR, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
16. Nabholtz JM, Bonneterre J, Buzdar AU, et al: Preliminary results of two multicenter trials comparing the efficacy and tolerability of Arimidex (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 57:A27, 1999 (abstr)
17. Dowsett M, Pfister C, Johnston SRD, et al: Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 5:2338-2343, 1999
18. UICC-Manual of Adult and Pediatric Medical Oncology, in Montardini S, Brunner K, Crowther D, et al (eds): Evaluation of the Cancer Patient and the Response to Treatment. Berlin, Germany, Springer, 1987, pp 22-38
19. Mouridsen H, Pérez-Carrión R, Becquart D, et al: Letrozole (Femara) versus tamoxifen: Preliminary data of a first-line clinical trial in postmenopausal women with locally advanced or metastatic breast cancer. Eur J Cancer 36:S88, 2000 (suppl 5, abstr 220)
20. Paridaens R, Dirix L, Beex L, et al: Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (BC) patients (Pts): Results of a randomized phase II trial. J Clin Oncol 19:83a, 2000 (abstr 316)
21. Ellmén J, Hakulinen P, Edwards M, et al: Hormonal effects of three toremifene (Fareston) doses in postmenopausal women with breast cancer. J Clin Oncol 19:102a, 2000 (abstr 395)
22. Ingle JN, Twito ID, Schaid DJ, et al: Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol 6:825-831, 1988
23. Paepke S, Apffelslaedt J, Eremin J, et al: Neo-adjuvant treatment of post-menopausal breast cancer patients with letrozole (Femara): A randomized multicenter study versus tamoxifen. Eur J Cancer 36:576, 2000 (suppl 5, abstr 179)
24. Miller WR: Biology of aromatase inhibitors: Pharmacology/ endocrinology within the breast. Endocr Relat Cancer 6:187-195, 1999
25. Bhatnagar AS, Miller WR: Pharmacology of inhibitors of estrogen synthesis, in Oettel M. Schillinger E (Eds). Handbook of Experimental Pharmacology, Vol. 135/II: Estrogens and Antiestrogens II. Pharmacology and Clinical Application of Estrogens and Antiestrogens. Berlin, Germany, Springer Verlag, 1999, pp 223-230
26. Long BJ, Tilghman SL, Yue W, et al: The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Molec Biol 67:293-304, 1998
27. Bhatnagar AS, Häusler A, Schieweck K, et al: Oestrogen depletion in advanced breast cancer: Why, how and where are we going?, in Advanced Breast Cancer: Reassessing Hormonal Therapy. Ciba Int Symp Ser 2:21-30, 1996
28. Lu Q, Yue W, Wang J, et al: The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 50:63-71, 1998
29. Lu Q, Liu Y, Long BJ, et al: The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 57:183-192, 1999
30. Brodie A, Lu Q, Liu Y, et al: Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 6:205-210, 1999